Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1674
    +0.0018 (+0.15%)
     

  • GBP/USD

    1.2478
    -0.0033 (-0.26%)
     

  • Bitcoin GBP

    50,819.45
    -587.61 (-1.14%)
     

  • CMC Crypto 200

    1,322.63
    -73.90 (-5.07%)
     

  • S&P 500

    5,100.61
    +52.19 (+1.03%)
     

  • DOW

    38,239.52
    +153.72 (+0.40%)
     

  • CRUDE OIL

    84.08
    +0.51 (+0.61%)
     

  • GOLD FUTURES

    2,347.90
    +5.40 (+0.23%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?

Margaret Patrick
Updated
AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?

The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.

Continue reading